pityriasis%20(tinea)%20versicolor
PITYRIASIS (TINEA) VERSICOLOR
Pityriasis (Tinea) versicolor is a fungal infection caused by Malassezia furfur. It is benign, superficial, and localized to the stratum corneum.
It may present as chronic or recurrent infection and may occur in healthy individuals.
It is more common in summer than winter months.
It presents with multiple well-demarcated macules or patches and finely scaled plaques with hypopigmentation or hyperpigmentation, hence the term "versicolor".
Lesions are usually found on the upper trunk, chest, back and shoulders, and may extend toward the neck, face and arms.

Definition

  • Pityriasis (tinea) versicolor is a common, benign, superficial fungal infection localized to the stratum corneum

Etiology

  • Caused by lipophilic yeasts, Malassezia species, part of the normal flora of the human skin

Signs and Symptoms

  • May present as chronic or recurrent infection & may occur in healthy individuals
    • More common in summer than winter months
  • Predominates in young adults when the sebaceous glands are most active
  • Presents w/ multiple well-demarcated macules or patches & finely scaled plaques w/ hypopigmentation orhyperpigmentation, hence the term “versicolor”
  • Tends to be asymptomatic & is mainly a cosmetic concern but pruritus may or may not be present
  • Usually found on the upper trunk, chest, back & shoulders, & may extend towards the neck, face & arms
  • Lesions do not tan along the normal skin

Risk Factors

Risk Factors that Promote Pityriasis (Tinea) Versicolor Infection:

  • High temp & high humidity
    • Prominent in tropical & subtropical regions
  • Occlusive clothing
  • Oily skin or application of oils to skin
  • Excessive sweating
  • Immunocompromised state, malnutrition & hereditary predisposition
  • Oral corticosteroid intake or Cushing’s disease
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
02 Nov 2017
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia. 
Stephen Padilla, 20 Nov 2017
Diclofenac reduces the use of antibiotics in women with uncomplicated lower urinary tract infection (UTI) but remains less effective than norfloxacin for symptom relief of UTI, according to a recent study. In addition, diclofenac appears to be associated with an elevated risk of pyelonephritis.